AAIPharma Charleston sterile manufacturing receives MHRA approval

Published: 23-Jan-2008
Ingredients Pharmaceutical

International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.


International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.

The MHRA approval certifies the plant to produce these products for shipment to countries in the EU and comes on the heels of a US$1.5m (Euro 1m) renovation of the plant. Along with prior approvals from the US FDA, this approval positions the plant to deliver aseptic contract manufacturing services to clients wishing to supply both commercial and clinical sterile drug products throughout the US and Europe.

'This investment and subsequent MHRA approval of our Charleston plant is in line with AAIPharma's goal to deliver high quality pharmaceutical services to meet the needs of the pharma and biotech industries,' said Lee Karras, sr vice president of global pharmaceutical services at AAIPharma.

  • Companies:
  • Alcami
See more

You may also like

Manufacturing

Alcami acquires TriPharm Services

Read more
US-based Alcami has acquired a new sterile fill-finish company near the Research Triangle Park in North Carolina

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Alcami acquires TriPharm Services

US-based Alcami has acquired a new sterile fill-finish company near the Research Triangle Park in North Carolina
Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Subscribe now